CT 7001

Drug Profile

CT 7001

Alternative Names: CT7001; ICEC0942

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Imperial College of Science, Technology and Medicine
  • Developer Carrick Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Acute myeloid leukaemia; Breast cancer; Small cell lung cancer

Most Recent Events

  • 05 Dec 2017 Adverse events and pharmacodynamics data from a preclinical trial in Breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 04 Dec 2017 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia released by Carrick Therapeutics
  • 30 Nov 2017 Phase-I clinical trials in Cancer in Ireland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top